The healthcare start-up aims to make India as one of its core engineering and research hubs, opening avenues for various research collaborations with hospitals and research institutes
CognitiveCare, a developer of pioneering and cutting-edge solutions for early disease detection and evolution, launched an Artificial Intelligence (AI) platform called MIHIC (Maternal Infant Health Insights and Cognitive Intelligence) to detect maternal, foetal, and infant health risks early.
According to the company, MIHIC is the only platform globally that leverages AI and advanced computing capabilities to analyse all medical, clinical, genetic, radiological, social, and lifestyle determinants to predict early signs of maternal, infant, and foetal risks in pregnant women. Also, MIHIC is reportedly the world’s first AI platform to predict and quantify the propensity towards 47 maternal, foetal, and infant health risks early in women. The company had raised $900,000 in the seed round at a pre-fund valuation of $8 million in early 2020.
Founded in 2018 by Venkata Narasimham Peri and Dr Suresh Attili, the early work in maternal and infant health proved that both the accuracy of prediction and the range of risks that can be predicted, which prompted them to focus on maternal and infant health. After bootstrapping the company with $300,000, they raised $900,000 in the seed round with a pre-money valuation of $8 million. The funds have been deployed to complete the first version of MIHIC and launch the sales and marketing efforts.
MIHIC offers benefits to various stakeholders. For instance, doctors can identify high-risk mothers for triage and targeted interventions very early, gather deep granular insights about mothers and infants for healthier patient outcomes and detect false positives and preventable outcomes during pregnancy.
Mothers/pregnant women can have a healthy and risk-free pregnancy, and are empowered to navigate their safer and healthier maternal journeys, to decide on timely interventions in collaboration with their caregivers to avoid/reduce potential risks. They can also avoid preventable surgical and medical outcomes (C-sections, prolonged labor, postpartum care, hemorrhage, and HAIs (Healthcare Acquired Infections).
Pharmaceutical companies can leverage population health insights for exploring new therapeutic focus areas, reduce time and cost in drug discovery and benefit from early detection of patient safety issues during drug/clinical trials.
Health insurance companies can stratify pregnant mothers by MIHIC scores, detect and identify avoidable medical interventions, work closely with caregivers to ensure optimal treatments for high-risk mothers and benefit from detailed cost estimation of pregnancy for a mother.
Governments can identify high-risk population segments and come up with specific policy and medical interventions early, save billions by detecting and preventing avoidable outcomes (C-sections, prolonged labour, etc.), empower girls and women from an early age about their future obstetric and gynaecological health and build safer, healthier homes and communities.
The healthcare start-up aims to make India as one of its core engineering and research hubs, opening avenues for various research collaborations with hospitals and research institutes.